Eris Lifesciences Ltd - Stock Valuation and Financial Performance

BSE: 540596 | NSE: ERIS | Pharmaceuticals & Drugs | Small Cap

Eris Lifesciences Share Price

834.85 -6.20 -0.74%
as on 28-Mar'24 16:01

DeciZen - make an informed investing decision on Eris Lifesciences

Overall Rating
Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

Eris Lifesciences stock performance -

mw4me loader
P/E Ratio (CD):
29.61
Market Cap:
11,442.7 Cr.
52-wk low:
557
52-wk high:
971

Is Eris Lifesciences Ltd an attractive stock to invest in?

1. Is Eris Lifesciences Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Eris Lifesciences Ltd is a good quality company.

2. Is Eris Lifesciences Ltd undervalued or overvalued?

The key valuation ratios of Eris Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Eris Lifesciences Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Eris Lifesciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Eris Lifesciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Eris Lifesciences Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 46.1%38.4%45.9%51.6%30.7%23.4%22.3%24.7%23.3%15.9%-
Value Creation
Index
2.41.82.42.71.30.70.70.80.70.2-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 5095465977508569821,0741,2121,3471,6851,841
Sales YoY Gr.-7.2%9.4%25.5%14.2%14.8%9.4%12.8%11.2%25.1%-
Adj EPS 4.96.39.616.720.22121.6263027.828.4
YoY Gr.-27.9%51.4%74.8%20.5%4.3%2.7%20.5%15.3%-7.1%-
BVPS (₹) 12.819.321.741.362.683.695.3115.8140.3161.3184.7
Adj Net
Profit
67.986.9132230277289293353408379386
Cash Flow from Ops. 89.690.1131200235223271375378292-
Debt/CF from Ops. 00001.60.8000.12.9-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 14.2%14.5%16.2%25.1%
Adj EPS 21.2%6.7%8.9%-7.1%
BVPS32.5%20.8%19.2%15%
Share Price - 5.3% 10.8% 45.4%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
4839.246.553.138.828.72424.623.418.516.4
Op. Profit
Mgn %
19.522.328.835.937.735.234.735.636.33235.1
Net Profit
Mgn %
13.415.922.330.732.529.527.329.130.22221
Debt to
Equity
00000.40.20000.4-
Working Cap
Days
7171687710111813013614514387
Cash Conv.
Cycle
1081211-4-4714132939

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 16.20%

Sales growth is good in last 4 quarters at 18.67%

Return on Equity has declined versus last 3 years average to 16.40%

Net Profit has been subdued in last 3 years 8.86%

Latest Financials - Eris Lifesciences Ltd.

Standalone Consolidated
TTM EPS (₹) 25.6 28.4
TTM Sales (₹ Cr.) 1,431 1,841
BVPS (₹.) 182.6 184.7
Reserves (₹ Cr.) 2,470 2,499
P/BV 4.61 4.55
PE 32.88 29.61
From the Market
52 Week Low / High (₹) 557.00 / 971.00
All Time Low / High (₹) 341.05 / 971.00
Market Cap (₹ Cr.) 11,443
Equity (₹ Cr.) 13.6
Face Value (₹) 1
Industry PE 48.2

Management X-Ray of Eris Lifesciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.0011.3710.9510.95
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Eris Lifesciences

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales5095465977498569821,0741,2121,3471,685
Operating Expenses 4104244254805336377067818621,148
Manufacturing Costs51211881119154321
Material Costs9910098134142154172238259352
Employee Cost 91126125131157191206229250346
Other Costs 216187191207227281310298310428
Operating Profit 99121172269322345368431485537
Operating Profit Margin (%) 19.4%22.3%28.8%35.9%37.6%35.1%34.3%35.5%36.0%31.9%
Other Income 4332526321692611
Interest 0001112322426
Depreciation 51620232636504365117
Exceptional Items 0000000000
Profit Before Tax 98109154270312317331394442405
Tax 27202024172635393630
Profit After Tax 7189135247295291297355406374
PAT Margin (%) 13.9%16.4%22.6%32.9%34.5%29.6%27.6%29.3%30.1%22.2%
Adjusted EPS (₹)5.16.59.718.021.421.221.826.229.928.1
Dividend Payout Ratio (%)0%0%62%0%0%0%13%21%20%26%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 1772663005678611,1491,2931,5721,9062,193
Share Capital 00014141414141414
Reserves 1772662995538481,1361,2801,5591,8932,180
Minority Interest44324251800-025
Debt010027400045699
Long Term Debt010027400045644
Short Term Debt00000000055
Trade Payables373725399184100103118125
Others Liabilities 524764102177229432844429
Total Liabilities 2703543927321,4281,4811,4371,7032,1133,471

Fixed Assets

Gross Block911041232548208389841,0061,0922,843
Accumulated Depreciation173252234878109152174275
Net Fixed Assets7572712327717618758549182,568
CWIP 000003422722
Investments 841671903033653567829452037
Inventories4558485665836994118131
Trade Receivables222425496784157140161293
Cash Equivalents 7610211867385258
Others Assets37294890149187186280316362
Total Assets 2703543927321,4281,4811,4371,7032,1133,471

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 9090131200235223271375378292
PBT 98109154270312317331394442405
Adjustment 11220-11431444449140
Changes in Working Capital 21-8-8-16-22-53-535-30-176
Tax Paid -30-23-35-53-70-72-52-69-83-77
Cash Flow From Investing Activity -83-92-44-184-590-5123-323-320-982
Capex -52-13-24-50-25-37-146-26-120-841
Net Investments -31-79-21-135-3835288-295-188490
Others 0000-527-3-19-3-11-631
Cash Flow From Financing Activity -20-84-24363-221-335-82-45688
Net Proceeds from Shares 0000010072
Net Proceeds from Borrowing -20-1-7373-200-176045785
Interest Paid 0000-10-22-2-2-4-23
Dividend Paid 00-83-1700-47-75-82-100
Others 000000-110-6-1124
Net Cash Flow 5-24-88-360-3014-2
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)50.1240.347.6856.941.328.9624.2824.7823.3318.25
ROCE (%)68.9349.2554.5662.5635.7626.5425.4427.625.2917.31
Asset Turnover Ratio2.31.781.651.330.790.680.740.790.730.63
PAT to CFO Conversion(x)1.271.010.970.810.80.770.911.060.930.78
Working Capital Days
Receivable Days14151518252841443947
Inventory Days32343125262826242826
Payable Days11013611486167208196155156126

Eris Lifesciences Ltd Stock News

Eris Lifesciences Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Eris Lifesciences on 28-Mar-2024 16:01 is ₹834.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 16:01 the market cap of Eris Lifesciences stood at ₹11,442.7.
The latest P/E ratio of Eris Lifesciences as of 28-Mar-2024 16:01 is 32.88.
The latest P/B ratio of Eris Lifesciences as of 28-Mar-2024 16:01 is 4.61.
The 52-week high of Eris Lifesciences is ₹971.0 and the 52-week low is ₹557.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Eris Lifesciences is ₹1,431 ( Cr.) .

About Eris Lifesciences Ltd

Eris Lifesciences founded by Mr Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and gynaecology. The company’s focus has been on developing, manufacturing and marketing products which are linked to lifestyle related disorders that are chronic in nature and are treated by superspecialist and specialist doctors. Eris features amongst the Top 30 companies in the Indian Branded Formulations Market.

The company’s core commitment is towards improving health care outcomes and adding value for all its stakeholders including patients, doctors, regulators, employees and business partners. The company is making ongoing efforts to innovate its products to bring the best clinical practices in health care industry to its customers.

The company’s product portfolio is primarily focused on therapeutic areas which are treated by super-specialist and specialist doctors such as Diabetologists, Endocrinologists, Cardiologists, Gastroenterologists, and Neurologists.

Business area of the company

The company develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. Its focus has been on developing products in the chronic and acute category which are linked to lifestyle related disorders.

History and milestones

  • 2007: Incorporation of the company.
  • 2007: Launched “Eris” division focused on cardiology and diabetes segment.
  • 2008: Launched “Nikkos” division focused on gastroenterology and orthopedics segment.
  • 2009: Launched “Adura” division focused on cardiology and diabetes segment.
  • 2011: Launched “Montana” division focused on gynecology and pediatrics segment.
  • 2012: Launched “Inspira” division focused on cardiology segment.
  • 2014: Launched “Victus” division focused on anti-diabetes segment.
  • 2014: Set up Assam Facility by the company.
  • 2015: Launched “Eris 2” division focused on pain management segment.
  • 2016: Acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited (now, Aprica Pharmaceuticals Private Limited).
  • 2016: Acquired 100.00% of the outstanding equity shares of Aprica Healthcare Private Limited.
  • 2016: Acquired 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited.
  • 2017: Acquired the trademarks ‘UNION’, ‘REUNION’ and ‘BON UNION’.
  • 2017: Eris acquires 40 trademarks from Amay Pharma
  • 2017: Eris acquires Pune based UTH Healthcare.
  • 2018: Eris entered into a distribution agreement with India Medtronic Private Limited.
  • 2019: Eris Lifesciences acquires trademark Zomelis from Novartis AG for $13 mn.
  • 2019: Eris partners with Pharmanutra S.P.A of Italy for Sideral.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.